Results 11 to 20 of about 4,376,584 (354)
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases [PDF]
Interstitial lung diseases represent a heterogeneous and wide group of diseases in which factors leading to disease initiation and progression are not fully understood.
F. Amati +13 more
semanticscholar +4 more sources
Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. [PDF]
Biomarkers have the potential to become central to the clinical evaluation and monitoring of patients with chronic fibrosing interstitial lung diseases with a progressive phenotype.
Y. Inoue +7 more
semanticscholar +2 more sources
The genetics of interstitial lung diseases [PDF]
Interstitial lung diseases (ILDs) are a set of heterogeneous lung diseases characterised by inflammation and, in some cases, fibrosis. These lung conditions lead to dyspnoea, cough, abnormalities in gas exchange, restrictive physiology (characterised by ...
R. Borie +7 more
semanticscholar +4 more sources
Importance Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure.
openaire +4 more sources
Progressive fibrosis in interstitial lung diseases — proposed definition and management [PDF]
Interstitial lung diseases may have an unpredictably progressive course, which is manifested as progression of pulmonary fibrosis, causing an increasing impairment of lung function affecting a poor prognosis.
Martusewicz-Boros, Magdalena Maria; National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland +3 more
core +2 more sources
Lung transplantation for interstitial lung disease [PDF]
Lung transplantation (LTx) can be a life-extending treatment option for patients with advanced and/or progressive fibrotic interstitial lung disease (ILD), especially idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis, sarcoidosis and connective tissue disease-associated ILD.
Siddhartha G. Kapnadak, Ganesh Raghu
openaire +3 more sources
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide.
F. Amati +6 more
semanticscholar +1 more source
Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a collection of systemic autoimmune disorders resulting in lung interstitial abnormalities or lung fibrosis.
G. Cerro Chiang, T. Parimon
semanticscholar +1 more source
Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis
Background Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis.
M. C. Schimmelpennink +7 more
doaj +1 more source
To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.
E. Matteson +14 more
semanticscholar +1 more source

